Literature DB >> 1703563

Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity.

M Tisdale1, T Schulze, B A Larder, K Moelling.   

Abstract

The C-terminal region of human immunodeficiency virus (HIV) reverse transcriptase (RT) contains the domain responsible for RNase H activity. To determine the importance of this RNase H domain, specific changes in the C-terminal region of a recombinant RT expressed in Escherichia coli were introduced by amino acid substitutions and specific deletions. The enzyme activities of purified wild-type and mutant RT/RNase H proteins, standardized for protein content, were compared by filter assays and thermal inactivation kinetics. A point mutation of His 539----Asn produced an enzyme with a marked thermolabile RNase H function (nine-fold increase in inactivation), whereas RT function was only marginally more labile than that of the wild-type (two-fold). A second mutation, His 539----Asp, impaired both enzyme activities to a similar degree (four- to five-fold). A C-terminal deletion of 19 amino acids (aa) (aa 540 to 558) and a C-terminal truncation of 21 aa (aa 540 to 560) reduced RT as well as RNase H activity. A 130 aa deletion enzyme exhibited no RNase H activity and insufficient RT activity to allow inactivation studies. Two mutants, the 19 aa deletion and His----Asn, were introduced into proviral HIV-1 DNA clones to determine whether changes in enzyme activity, particularly RNase H activity, affected virus infectivity. Both mutants were non-infectious, indicating that the C-terminal 19 to 21 amino acids and His 539 of the RT/RNase H protein are essential for HIV replication. These results are consistent with the assumption that RNase H is essential for the infectivity of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703563     DOI: 10.1099/0022-1317-72-1-59

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  58 in total

1.  Effects of homology length in the repeat region on minus-strand DNA transfer and retroviral replication.

Authors:  Q Dang; W S Hu
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Expression of Moloney murine leukemia virus RNase H rescues the growth defect of an Escherichia coli mutant.

Authors:  A G Campbell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

5.  Defects in Moloney murine leukemia virus replication caused by a reverse transcriptase mutation modeled on the structure of Escherichia coli RNase H.

Authors:  A Telesnitsky; S W Blain; S P Goff
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 6.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; W Gregory Alvord; Eddy Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.

Authors:  Lei Wang; Jing Tang; Andrew D Huber; Mary C Casey; Karen A Kirby; Daniel J Wilson; Jayakanth Kankanala; Jiashu Xie; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2018-07-17       Impact factor: 6.514

9.  6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H.

Authors:  Lei Wang; Jing Tang; Andrew D Huber; Mary C Casey; Karen A Kirby; Daniel J Wilson; Jayakanth Kankanala; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2018-07-17       Impact factor: 6.514

10.  Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer.

Authors:  Mary Jane McWilliams; John G Julias; Stefan G Sarafianos; W Gregory Alvord; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.